FDA approves Takeda’s Orzeyful for narcolepsy type 1The U.S. FDA has approved Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist Orzeyful (oveporexton) as the first therapy designed to address the underlying cause of narcolepsy type 1 in adults. Announced Aug. 5, approval of the first-in-class orexin treatment marks the second worldwide, following the China National Medical Products Administration’s clearance on July 22.